Literature DB >> 8647877

(1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase.

A Bielawska1, M S Greenberg, D Perry, S Jayadev, J A Shayman, C McKay, Y A Hannun.   

Abstract

In this study, we have examined the cellular and biochemical activities of the ceramide analog (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-erythro-MAPP). Addition of 5 microM D-e-MAPP to HL-60 human promyelocytic leukemia cells resulted in a concentration- and time-dependent growth suppression accompanied by an arrest in the G0/G1 phase of the cell cycle; thus mimicking the action of exogenous ceramides. Its enantiomer L-e-MAPP was without effect. Two lines of evidence suggested that D-e-MAPP may not function as a direct analog of ceramide. First, D-e-MAPP possesses a stereochemical configuration opposite to that of D-erythro-ceramide. Second, D-e-MAPP failed to activate ceramide-activated protein phosphatase in vitro. Therefore, we examined if D-e-MAPP functioned indirectly by modulating endogenous ceramide levels. The addition of D-e-MAPP to cells, but not L-e-MAPP, caused a time- and concentration-dependent elevation in endogenous ceramide levels reaching greater than 3-fold over baseline following 24 h of treatment. Both D-e-MAPP and L-e-MAPP underwent similar uptake by HL-60 cells. D-e-MAPP was poorly metabolized, and remained intact in cells, whereas L-e-MAPP underwent a time- and concentration-dependent metabolism; primarily through N-deacylation. In vitro, L-e-MAPP was metabolized by alkaline ceremidase to an extent similar to that seen with C16-ceramide. D-e-MAPP was not metabolized. Instead, D-e-MAPP inhibited alkaline ceramidase activity in vitro with an IC50 of 1-5 microM. D-e-MAPP did not modulate the activity of other ceramide metabolizing enzymes in vitro or in cells, and it was a poor inhibitor of acid ceramidase (IC50>500 microM). Finally, D-e-MAPP inhibited the metabolism of L-e-MAPP in cells. These studies demonstrate that D-e-MAPP functions as an inhibitor of alkaline ceramidase in vitro and in cells resulting in elevation in endogenous levels of ceramide with the consequent biologic effects of growth suppression and cell cycle arrest. These studies point to an important role for ceramidases in the regulation of endogenous levels of ceramide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647877     DOI: 10.1074/jbc.271.21.12646

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Sphingolipid metabolism in the regulation of bioactive molecules.

Authors:  C Luberto; Y A Hannun
Journal:  Lipids       Date:  1999       Impact factor: 1.880

Review 2.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

3.  Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

Authors:  Alicja Bielawska; Jacek Bielawski; Zdzislaw M Szulc; Nalini Mayroo; Xiang Liu; AiPing Bai; Saeed Elojeimy; Barbara Rembiesa; Jason Pierce; James S Norris; Yusuf A Hannun
Journal:  Bioorg Med Chem       Date:  2007-08-24       Impact factor: 3.641

4.  Discovery and evaluation of inhibitors of human ceramidase.

Authors:  Jeremiah M Draper; Zuping Xia; Ryan A Smith; Yan Zhuang; Wenxue Wang; Charles D Smith
Journal:  Mol Cancer Ther       Date:  2011-09-01       Impact factor: 6.261

5.  Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs.

Authors:  Aiping Bai; Zdzislaw M Szulc; Jacek Bielawski; Jason S Pierce; Barbara Rembiesa; Silva Terzieva; Cungui Mao; Ruijuan Xu; Bill Wu; Christopher J Clarke; Benjamin Newcomb; Xiang Liu; James Norris; Yusuf A Hannun; Alicja Bielawska
Journal:  Bioorg Med Chem       Date:  2014-10-22       Impact factor: 3.641

6.  Sphingolipid metabolism regulates development and lifespan in Caenorhabditis elegans.

Authors:  Roy G Cutler; Kenneth W Thompson; Simonetta Camandola; Kendra T Mack; Mark P Mattson
Journal:  Mech Ageing Dev       Date:  2014-11-28       Impact factor: 5.432

7.  Acid ceramidase (ASAH1) is a global regulator of steroidogenic capacity and adrenocortical gene expression.

Authors:  Natasha C Lucki; Sibali Bandyopadhyay; Elaine Wang; Alfred H Merrill; Marion B Sewer
Journal:  Mol Endocrinol       Date:  2012-01-19

8.  Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway.

Authors:  P Xia; J R Gamble; K A Rye; L Wang; C S Hii; P Cockerill; Y Khew-Goodall; A G Bert; P J Barter; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

9.  Potent inhibition of Acid ceramidase by novel B-13 analogues.

Authors:  Denny Proksch; Jan Jasper Klein; Christoph Arenz
Journal:  J Lipids       Date:  2010-12-09

Review 10.  Molecular targeting of acid ceramidase: implications to cancer therapy.

Authors:  Youssef H Zeidan; Russell W Jenkins; John B Korman; Xiang Liu; Lina M Obeid; James S Norris; Yusuf A Hannun
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.